PreCision Dermatology is a spin-out of the dermatology subsidiary of Collegium Pharmaceutical. PreCision develops and markets proprietary formulations of currently approved dermatological products. The primary targeted therapeutic areas are: atopic dermatitis (eczema), acne, rosacea, emollients/anti-aging and steroid responsive dermatoses. PreCision was acquired by Valeant Pharmaceuticals, Inc. (NYSE: VRX) in July 2014 in an all cash transaction for an aggregate purchase price of $500 million.
30 Rowes Wharf, Boston, MA, 02110
